CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
CONCLUSIONS: Our study demonstrates that miR-10b-CADM2-FAK/AKT axis plays an important role in HCC metastasis, which might be a novel potential therapeutic option for HCC treatment. PMID: 29506532 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2018 Category: Cancer & Oncology Authors: Li D, Zhang Y, Zhang H, Zhan C, Li X, Ba T, Qiu Z, E F, Lv G, Zou C, Wang C, Si L, Zou C, Li Q, Gao X Tags: J Exp Clin Cancer Res Source Type: research
Multiple primary non-breast tumors in breast cancer survivors.
CONCLUSIONS: Older age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status. PMID: 29502170 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2018 Category: Cancer & Oncology Authors: Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, Intra M, Sacchini V, Galimberti V Tags: J Cancer Res Clin Oncol Source Type: research
Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
Conclusions: The frequency of 13 causative founder variants in Podkarpacie was lower than in other regions of Poland. Testing of three BRCA1 mutations (c.5266dupC, c.181 T > G, c.676delT) should be considered a sensitive test panel. PMID: 29492181 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 2, 2018 Category: Cancer & Oncology Authors: Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J Tags: Hered Cancer Clin Pract Source Type: research
Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.
Abstract Breast cancer is the leading cause of cancer mortality among women in developing countries. Timely and accurate histopathological diagnosis of breast cancer is critical to delivering high-quality breast cancer care to patients in low- and middle-income countries (LMIC). The most important prognostic factors in breast cancer along with tumor size and nodal status are tumor grade, estrogen receptor status, as well as HER2 status in countries where specific targeted therapies are available. In addition, detailed and complete cancer registry data are needed to assess a country's disease burden and guide disea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Martei YM, Pace LE, Brock JE, Shulman LN Tags: Clin Lab Med Source Type: research
Core Needle Biopsy of the Breast: An Evaluation of Contemporary Data.
This article highlights contemporary diagnostic criteria and outcome data that would support an evidence-based approach to the management of these nonmalignant lesions of the breast diagnosed on CNB. PMID: 29413652 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Calhoun BC Tags: Surg Pathol Clin Source Type: research
Lobular Carcinoma In Situ.
Abstract Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasive carcinoma after classic LCIS diagnosis is approximately 9 to 10 times that of the general population. Classic LCIS diagnosed on core biopsy with concordant imaging and pathologic findings does not mandate surgical excision, and margin status is not reported. The identification of variant LCIS in a needle core biopsy specimen mandates surgical excision, regardless of radiologic-pathologic concordance. The presence of variant LCIS close to the surgical margin of a resection specim...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Wen HY, Brogi E Tags: Surg Pathol Clin Source Type: research
Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results.
Abstract Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected resul...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Allison KH Tags: Surg Pathol Clin Source Type: research
Genotype-Phenotype Correlations in Breast Cancer.
Abstract Only a few breast cancer histologic subtypes harbor distinct genetic alterations that are associated with a specific morphology (genotype-phenotype correlation). Secretory carcinomas and adenoid cystic carcinomas are each characterized by recurrent translocations, and invasive lobular carcinomas frequently have CDH1 mutations. Solid papillary carcinoma with reverse polarity is a rare breast cancer subtype with a distinctive morphology and recently identified IDH2 mutations. We review the clinical and pathologic features and underlying genetic alterations of those breast cancer subtypes with established ge...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Marotti JD, Schnitt SJ Tags: Surg Pathol Clin Source Type: research
Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Abstract Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the brea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Bossuyt V Tags: Surg Pathol Clin Source Type: research
The Drug-Drug Interaction Profile of Presatovir.
This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3. As expected, based on the role of CYP3A in...
Source: Clinical Breast Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Xin Y, Weng W, Murray BP, Eisenberg EJ, Chien JW, Ling J, Silverman JA Tags: J Clin Pharmacol Source Type: research
Breast cancer: Recurrent fusions in endocrine-resistant disease.
PMID: 29405202 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 6, 2018 Category: Cancer & Oncology Authors: Romero D Tags: Nat Rev Clin Oncol Source Type: research
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors. PMID: 29401002 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J Tags: J Clin Oncol Source Type: research
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
CONCLUSIONS: Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA. PMID: 29404838 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Rodríguez-Balada M, Roig B, Melé M, Salvat M, Martorell L, Borràs J, Gumà J Tags: Clin Transl Oncol Source Type: research
Predictive factors of satisfaction and quality of life after immediate breast reconstruction using the BREAST-Q ©.
CONCLUSIONS: The type of treatment and lymphedema modify the patients' quality of life. Nicotine dependence is associated with lower satisfaction with the breast and with the outcome. RELEVANCE TO CLINICAL PRACTICE: This study suggests the need for multi-disciplinary attention during the first year of adjuvant treatment despite the benefits of immediate reconstruction. It shows the need for preoperative assessment of the level of nicotine dependence, anxiety and depression of smoking patients before preoperative counseling. This article is protected by copyright. All rights reserved. PMID: 29396899 [PubMed - as s...
Source: Clinical Breast Cancer - February 3, 2018 Category: Cancer & Oncology Authors: Cereijo-Garea C, Pita-Fernández S, Acea-Nebril B, Rey-Villar R, García-Novoa A, Varela-Lamas C, Builes-Ramirez S, Seoane-Pillado T, Balboa-Barreiro V Tags: J Clin Nurs Source Type: research
Selenium in infant formula milk.
Abstract Formula-based animal milk is an alternative source of infant nutrition in many cases when breastfeeding is unacceptable or inaccessible; however, these replacements often have low selenium levels. The composition of infant formula milk should be as close as possible to that of human breast milk, both in content and chemical speciation. Selenium is an essential trace element for infants. Generally, human breast milk is the ideal food to ensure adequate infant Se intake. However, to date, sodium selenite or sodium selenate has been used as selenium supplementation in infant formula milk in most countries. T...
Source: Clinical Breast Cancer - February 1, 2018 Category: Cancer & Oncology Authors: He MJ, Zhang SQ, Mu W, Huang ZW Tags: Asia Pac J Clin Nutr Source Type: research
Label-Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses.
CONCLUSIONS AND CLINICAL RELEVANCE: The present dataset provides a list of candidate biomarkers that could be used for early differentiation diagnosis and prognosis of breast cancer with lymph node metastasis. This article is protected by copyright. All rights reserved. PMID: 29384592 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Chen L, Zhao W, He J, Li L, Meng D, Cai D, Yu J, Chen D, Wu Y, Zhou T Tags: Proteomics Clin Appl Source Type: research
Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
Conclusion These findings support current recommendations for systemic imaging in the setting of locoregional recurrence, particularly for patients with lymph node or chest wall recurrences. Because most patients with isolated locoregional recurrence will be recommended locoregional treatment, early identification of distant metastases through routine systemic imaging may spare them treatments unlikely to extend their survival. PMID: 29384721 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, Yu M, McKellar D, Winchester DP, Greenberg CC, Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Grou Tags: J Clin Oncol Source Type: research
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Abstract Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype. PMID: 29385237 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE Tags: Clin Pharmacol Ther Source Type: research
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Abstract Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. The risk of bias of selected studies was evaluated and the relevant data items were extracted, summarized and analyzed. A total of 21 studies were discussed in this review r...
Source: Clinical Breast Cancer - January 30, 2018 Category: Cancer & Oncology Authors: Nahm N, Mee S, Marx G Tags: Asia Pac J Clin Oncol Source Type: research
Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds.
Conclusion: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives. PMID: 29371908 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 28, 2018 Category: Cancer & Oncology Authors: Dominguez-Valentin M, Evans DGR, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E Tags: Hered Cancer Clin Pract Source Type: research
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC. PMID: 29373071 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J Tags: J Clin Oncol Source Type: research
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Conclusion Equivalence for efficacy was demonstrated between SB3 and TRZ on the basis of the ratio of bpCR rates. Safety and immunogenicity were comparable. PMID: 29373094 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M, Semiglazov V, Song S, Lim J Tags: J Clin Oncol Source Type: research
Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study.
Abstract Purpose Being diagnosed with cancer causes major psychological distress; however, a majority of patients lack psychological support during this critical period. Internet interventions help patients overcome many barriers to seeking face-to-face support and may thus close this gap. We assessed feasibility and efficacy of Web-based stress management (STREAM [Stress-Aktiv-Mindern]) for newly diagnosed patients with cancer. Patients and Methods In a randomized controlled trial, patients with cancer who had started first-line treatment within the previous 12 weeks were randomly assigned to a therapist-guided W...
Source: Clinical Breast Cancer - January 25, 2018 Category: Cancer & Oncology Authors: Urech C, Grossert A, Alder J, Scherer S, Handschin B, Kasenda B, Borislavova B, Degen S, Erb J, Faessler A, Gattlen L, Schibli S, Werndli C, Gaab J, Berger T, Zumbrunn T, Hess V Tags: J Clin Oncol Source Type: research
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
TP, Ejlertsen B Abstract Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of postmenopausal women with hormone receptor-positive early breast cancer treated with 5 years of endocrine therapy alone. Patients and Methods Using the population-based Danish Breast Cancer Cooperative Group database, follow-up data were collected on all patients diagnosed from 2000 through 2003 who, by nationwide guidelines,...
Source: Clinical Breast Cancer - January 25, 2018 Category: Cancer & Oncology Authors: Lænkholm AV, Jensen MB, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, Ferree S, Schaper C, Nielsen TO, Haffner T, Kibøl T, Møller Talman ML, Bak Jylling AM, Tabor TP, Ejlertsen B Tags: J Clin Oncol Source Type: research
Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
Conclusion The tailored and interactive iCanDecide Web site, which focused on knowledge building and values clarification, positively affected high-quality decisions largely by improving knowledge compared with static online information. To be effective, future patient-facing decision tools should be integrated into the clinical workflow to improve decision making. PMID: 29364772 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 24, 2018 Category: Cancer & Oncology Authors: Hawley ST, Li Y, An LC, Resnicow K, Janz NK, Sabel MS, Ward KC, Fagerlin A, Morrow M, Jagsi R, Hofer TP, Katz SJ Tags: J Clin Oncol Source Type: research
Exogenous reproductive hormone use in breast cancer survivors and previvors.
Abstract Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure f...
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Vaz-Luis I, Partridge AH Tags: Nat Rev Clin Oncol Source Type: research
Survivin is a negative prognostic factor in malignant pleural effusion.
ro F, Otero-Candelera R Abstract SURVIVIN: is a well-known member of the inhibitor of apoptosis family, and has been related with increased tumour aggressivity, both in tissue and in pleural fluid. OBJECTIVES: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. METHODS: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 ...
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Arellano-Orden E, Romero-Romero B, Sánchez-López V, Martín-Juan J, Rodríguez-Panadero F, Otero-Candelera R Tags: Eur J Clin Invest Source Type: research
Transforming growth factor beta 1 (TGF β1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.
CONCLUSION: The present study indicates that TGFB1 variants have subtype-specific roles in BC and may switch from tumor suppressor to promoter during tumor development, consistent with TGFβ1 dual role in BC pathogenesis. PMID: 29362917 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Vitiello GAF, Guembarovski RL, Hirata BKB, Amarante MK, de Oliveira CEC, de Oliveira KB, Cebinelli GCM, Guembarovski AL, Campos CZ, Watanabe MAE Tags: J Cancer Res Clin Oncol Source Type: research
Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients.
CONCLUSIONS: The present paper reports for the first time on the prognostic value of miRNA-494 in invasive breast cancer. Particularly, detection of miRNA-494 could benefit patients with node-negative breast cancer in identifying subgroups with aggressive disease. Based on our experience, the developed automatic ISH method to visualize altered levels of miRNAs-494, -205, -21 and -126 could be applied to routine pathology diagnostics providing that conditions of tissue treatment, especially fixation delays, are managed. PMID: 29362919 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Gurvits N, Autere TA, Repo H, Nykänen M, Kuopio T, Kronqvist P, Talvinen K Tags: J Cancer Res Clin Oncol Source Type: research
Breast Cancer Stage at Diagnosis in a New Jersey Cancer Education and Early Detection Site.
This study will provide a first snapshot of the effectiveness of the New Jersey program, by comparing stage at diagnosis for enrollees as compared with nonenrollees who received definitive treatment for breast cancer at the same academic medical center. MATERIALS AND METHODS: A retrospective analysis of 5 years of breast cancer data abstracted from the Cancer Registry of a large urban hospital in the Northeast United States. Bivariate analysis and logistic regression were utilized. RESULTS: One thousand forty women were screened for and diagnosed with breast cancer at this site; they were more likely to be racially (P
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Jerome-D'Emilia B, Kushary D, Burrell SA, Suplee PD, Hansen K Tags: Am J Clin Oncol Source Type: research
Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
Abstract Purpose Metabolic syndrome is associated with an increased risk of cardiovascular disease, type 2 diabetes, and breast cancer recurrence in survivors of breast cancer. This randomized controlled trial assessed the effects of a 16-week combined aerobic and resistance exercise intervention on metabolic syndrome, sarcopenic obesity, and serum biomarkers among ethnically diverse, sedentary, overweight, or obese survivors of breast cancer. Methods Eligible survivors of breast cancer (N = 100) were randomly assigned to exercise (n = 50) or usual care (n = 50). The exercise group participated in supervised moder...
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE Tags: J Clin Oncol Source Type: research
Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial.
This study aimed to test a group psychosocial intervention focused on improving disturbances of body image (BI), sexual functioning, and quality of life in breast cancer (BC) survivors. Methods A prospective, randomized controlled trial was conducted to assess the efficacy of an 8-week group intervention in women after BC treatment. The manual-based intervention combined two powerful ingredients: expressive guided-imagery exercises integrated within a model of group-therapy principles. The intervention facilitates exploration of identity, the development of new self-schemas, and personal growth. In addition, the interventi...
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Esplen MJ, Wong J, Warner E, Toner B Tags: J Clin Oncol Source Type: research
Does breast density measured through population-based screening independently increase breast cancer risk in Asian females?
Abstract Purpose: The purpose of this study was to investigate the effects of breast density on breast cancer risk among women screened via a nationwide mammographic screening program. Patients and methods: We conducted a nested case-control study for a randomly selected population of 1,561 breast cancer patients and 6,002 matched controls from the National Cancer Screening Program. Breast density was measured and recorded by two independent radiologists using the Breast Imaging Reporting and Data System (BI-RADS). Associations between BI-RADS density and breast cancer risk were evaluated according to screeni...
Source: Clinical Breast Cancer - January 20, 2018 Category: Cancer & Oncology Authors: Park B, Cho HM, Lee EH, Song S, Suh M, Choi KS, Kang BJ, Ko K, Yi A, Jung HK, Cha JH, Jun JK Tags: Clin Epidemiol Source Type: research
Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.
Abstract There has been tremendous progress in detection of breast cancer in postmenopausal women, resulting in two-thirds of women surviving more than 20 years after treatment. However, breast cancer remains the leading cause of cancer-related deaths in premenopausal women. Breast cancer is increasing in younger women due to changes in life-style as well as those at high risk as carriers of mutations in high-penetrance genes. Premenopausal women with breast cancer are more likely to be diagnosed with aggressive tumours and therefore have a lower survival rate. Mammography plays an important role in detecting...
Source: Clinical Breast Cancer - January 20, 2018 Category: Cancer & Oncology Authors: Shaheed SU, Tait C, Kyriacou K, Linforth R, Salhab M, Sutton C Tags: Clin Proteomics Source Type: research
BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway.
Conclusions: The spectrum of BRCA1 and BRCA2 mutations in the carrier population at Norway's largest cancer genetics clinic is diverse, and with a weaker founder effect than previously described. As a consequence, retesting the families that previously have been tested with specific tests/founder mutation tests should be a prioritised strategy to find more mutation positive families and possibly prevent cancer in healthy relatives. PMID: 29339979 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 18, 2018 Category: Cancer & Oncology Authors: Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L Tags: Hered Cancer Clin Pract Source Type: research
Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Abstract Purpose The 21-gene recurrence score (RS) breast cancer assay is clinically used to quantify risk of 10-year distant recurrence by category (low,
Source: Clinical Breast Cancer - January 17, 2018 Category: Cancer & Oncology Authors: Holowatyj AN, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS Tags: J Clin Oncol Source Type: research
Epstein Barr virus and invasive mammary carcinomas: EBNA, EBERs and molecular profile in a population of West Algeria.
The objective of this study is to determine the association of EBV infection with infiltrating ductal carcinomas (IDC). This descriptive study was carried out in the laboratory of developmental biology and differentiation, from 2012 to 2014. Of 39 cases, we determined the clinicopathological characteristics of the population. Of the 23 cases of IDC, we implemented the techniques Elisa, immunohistochemistry and in situ hybridization. To determine the serological profile, overexpression of onco-proteins EBNA-1, HER2, the mitotic index Ki67 and detection of the presence of the viral genome. The mean age is 57.40±4, SBR...
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yahia R, Zaoui C, Derbale W, Boudi H, Chebloune Y, Sahraoui T, Elkebir FZ Tags: Ann Biol Clin (Paris) Source Type: research
Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
CONCLUSIONS: Our work provides experimental evidence on the association of 6PGD with poor prognosis in breast cancer and suggests that 6PGD inhibition may represent a potential therapeutic strategy to augment chemotherapy efficacy in breast cancer. PMID: 29340974 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yang X, Peng X, Huang J Tags: Clin Transl Oncol Source Type: research
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL. PMID: 29328860 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2018 Category: Cancer & Oncology Authors: Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ Tags: J Clin Oncol Source Type: research
Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
We examined the potential of the reversible P2Y12 inhibitor ticagrelor, an agent used clinically to prevent cardiovascular and cerebrovascular events, to reduce tumor growth and metastasis. In vitro, MCF-7, MDA-MB-468, and MDA-MB-231 human mammary carcinoma cells exhibited decreased interaction with platelets treated with ticagrelor compared to untreated platelets. Prevention of tumor cell-platelet interactions through pretreatment of platelets with ticagrelor did not improve natural killer cell-mediated tumor cell killing of K562 myelogenous leukemia target cells. Additionally, ticagrelor had no effect on proliferation of...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M Tags: Clin Exp Metastasis Source Type: research
Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.
Abstract During epithelial-mesenchymal transition (EMT) epithelial cancer cells trans-differentiate into highly-motile, invasive, mesenchymal-like cells giving rise to disseminating tumor cells. Only few of these disseminated cells successfully metastasize. Immune cells and inflammation in the tumor microenvironment was shown to drive EMT, but few studies investigated the consequences of EMT on tumor immunosurveillance. In addition to initiating metastasis, we demonstrate that EMT confers increased susceptibility to NK cells and contributes, in part, to the inefficiency of the metastatic process. Depletion of NK c...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG Tags: J Clin Invest Source Type: research
High nuclear MSK1 is associated with longer survival in breast cancer patients.
Abstract PURPOSE: Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, evaluating its prognostic significance. METHODS: A large cohort of 1902 early stage invasive breast cancer patients was use...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Pu X, Storr SJ, Ahmad NS, Rakha EA, Green AR, Ellis IO, Martin SG Tags: J Cancer Res Clin Oncol Source Type: research
Systemic therapy for brain metastases.
Abstract Central nervous system metastases cause grave morbidity in patients with advanced malignancies. Lung cancer, breast cancer, and melanoma are the three most common causes of brain metastases. Although the exact incidence of brain metastases is unclear, there appears to be an increasing incidence which has been attributed to longer survival, better control of systemic disease, and better imaging modalities. Until recently surgical resection of solitary or symptomatic brain metastases, and radiation therapy (either whole-brain radiation therapy or stereotactic radiation) were the mainstay of treatment for pa...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Venur VA, Karivedu V, Ahluwalia MS Tags: Handb Clin Neurol Source Type: research
Abstract Leptomeningeal metastasis (LM) results from dissemination of cancer cells to both the leptomeninges (pia and arachnoid) and cerebrospinal fluid (CSF) compartment. Breast cancer, lung cancer, and melanoma are the most common solid tumors that cause LM. Recent approval of more active anticancer therapies has resulted in improvement in survival that is partly responsible for an increased incidence of LM. Neurologic deficits, once manifest, are mostly irreversible, and often have a significant impact on patient quality of life. LM-directed therapy is based on symptom palliation, circumscribed use of neurosurg...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Taillibert S, Chamberlain MC Tags: Handb Clin Neurol Source Type: research
Brain metastases: epidemiology.
Abstract Brain metastases (BM) are the most commonly diagnosed type of central nervous system tumor in the United States. Estimates of the frequency of BM vary significantly, as there is no nationwide reporting system for metastases. BM may be the first sign of a previously undiagnosed cancer, or occur years or decades after the primary cancer was diagnosed. Incidence of BM varies significantly by primary cancer site. Lung, breast, and melanoma continue to be the leading cause of BM. These tumors are increasingly more common as new therapeutics, advanced imaging, and improved screening have led to lengthened survi...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Ostrom QT, Wright CH, Barnholtz-Sloan JS Tags: Handb Clin Neurol Source Type: research
Metastatic diseases of the central nervous system - neuropathologic aspects.
Abstract A large percentage of patients with cancer will develop brain metastases, and many of them will die within a few months following diagnosis of intracranial metastasis. Although the majority of the central nervous system metastases are derived from a well-known primary neoplasm, about 5-10% of brain metastases are from an unknown source, making the tissue diagnosis a first step in the search for a primary malignancy. The pathologist utilizes several immunohistochemical and molecular diagnostic tools for such investigation, helping the clinical oncologist to narrow down the clinical and radiologic explorati...
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Lopes MBS Tags: Handb Clin Neurol Source Type: research
Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory.
Conclusion: These results provide the actual percentage of family or personal history of cancer that can be attributed to pathogenic or likely pathogenic variants in one or more of the genes on our panel and corroborate the utility of multi-gene panels over sequential testing to identify individuals with an inherited predisposition to cancer. PMID: 29308099 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 10, 2018 Category: Cancer & Oncology Authors: Gardner SA, Weymouth KS, Kelly WS, Bogdanova E, Chen W, Lupu D, Suhl J, Zeng Q, Geigenmüller U, Boles D, Okamoto PM, McDowell G, Hayden MA, Nagan N Tags: Hered Cancer Clin Pract Source Type: research
Indoor Tanning a Gianus Bifrons: Vitamin D and Human Cancer.
Abstract Despite it is now undeniable that indoor tanning exposure is associated with a number of skin cancers, its favorable effects on vitamin D status may bear some underestimated and currently unexplored health benefits. Vitamin D is a fat-soluble vitamin naturally present in a limited number of foods, the concentration of which largely depends on ultraviolet (UV) B sources exposure in humans. A strong, graded, and inverse association has been documented between serum vitamin D and the risk of developing certain types of malignancy, especially colorectal, breast, lung, bladder, and kidney cancers. The overall ...
Source: Clinical Breast Cancer - January 8, 2018 Category: Cancer & Oncology Authors: Lippi G, Cervellin G, Danese E Tags: Adv Clin Chem Source Type: research
Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer.
Abstract The molecular diagnosis of the cancer mutational status is essential for modern clinical laboratory medicine. Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma. The allele-specific polymerase chain reaction, high-resolution melting, and Sanger sequencing are used for detecting and identifying gene mutations in many clinical laboratories. The locked nucleic acid (LNA) is a class of nucleic acid analogs that contain a methylene bridge connecting the 2' oxygen and 4' carbon in the ribose moiety. This methyle...
Source: Clinical Breast Cancer - January 8, 2018 Category: Cancer & Oncology Authors: Ishige T, Itoga S, Matsushita K Tags: Adv Clin Chem Source Type: research
GSTP1 methylation in cancer: a liquid biopsy biomarker?
Abstract The coding region of GSTP1 gene is preceded by a large CpG-rich region that is frequently affected by methylation. In many cancer types, GSTP1 is affected by hypermethylation and, as a consequence, it has a low expression. The aim of this review is to give an overview on GSTP1 methylation studies with a special focus on liquid biopsy, thus to summarize methods, results, sample types, different diseases, to have a complete information regarding this promising epigenetic biomarker. We used all the most valuable scientific search engines (PubMed, Medline, Scopus and Web of Science) searching the following ke...
Source: Clinical Breast Cancer - January 6, 2018 Category: Cancer & Oncology Authors: Gurioli G, Martignano F, Salvi S, Costantini M, Gunelli R, Casadio V Tags: Clin Chem Lab Med Source Type: research